When it comes to transforming cancer treatment, one venture capital firm is making waves.
Yosemite, based in San Francisco, CA, has reportedly raised over $200 million for its second investment fund—a major step toward backing groundbreaking oncology startups.
Ambitious Fundraising Goals
Forbes reports that Yosemite’s new fund is aiming even higher, with a target of $350 million.
This shows the firm’s serious commitment to supporting innovative biotech and healthcare companies tackling cancer.
From Emerson Collective to Independent Venture Firm
Yosemite was founded in 2015 by Reed Jobs with a clear mission: to invest in technologies and solutions that could make cancer a non-lethal disease.
The firm originally started under the umbrella of Emerson Collective, but in 2023 it became fully independent, giving it greater flexibility to pursue its vision.
A Growing Portfolio of Life-Changing Investments
The firm has already built an impressive portfolio of investments in biotech and healthcare innovation.
Each project reflects its goal of making meaningful progress in cancer treatment.
You can explore the list of investments to see where Yosemite is putting its focus next.
What Lies Ahead
With the second fund underway and ambitious targets in place, the big question now is: what’s next for Yosemite and the startups it supports?
If the firm continues on this trajectory, we could see some transformative breakthroughs in oncology in the near future.
Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn